Outcome

This study highlights the significant impact of hyperbaric oxygen (HBO) therapy on inflammatory factors in keloid tissues. It was observed that keloid tissues exhibit markedly higher levels of inflammatory mediators such as IL-12p40 MIP-1β PDGF-BB and IL-1Ra when compared to normal skin samples. The application of HBO therapy resulted in distinct changes in these inflammatory mediator levels suggesting that HBO therapy plays a crucial role in reducing inflammation in keloid tissues.

Introduction

Keloids are a form of exaggerated scarring that extends beyond the original wound boundaries commonly linked with heightened inflammation. Understanding how to mitigate this inflammatory response is crucial for developing effective treatments. This study explores the effects of hyperbaric oxygen (HBO) therapy on inflammation in keloid patients by examining key inflammatory markers including interleukin-12p40 (IL-12p40) macrophage inflammatory protein-1β (MIP-1β) platelet-derived growth factor-BB (PDGF-BB) and interleukin-1 receptor antagonist (IL-1Ra). Thirty patients were classified into three groups: keloid patients treated with HBO therapy keloid patients without HBO therapy and individuals with normal skin. Results showed that HBO therapy significantly reduced the expression of these inflammatory factors and decreased inflammatory infiltration in keloid tissues. These findings suggest that HBO therapy may play a pivotal role in attenuating inflammation associated with keloid formation providing a scientific basis for its use in managing keloid patients.

Results

The study’s findings reveal a significant impact of Hyperbaric Oxygen Therapy (HBOT) on inflammatory mediators in keloid tissues. Analysis was performed on three groups: keloid patients treated with HBOT (group A) keloid patients without HBOT (group B) and normal skin controls (group C).

Keloid tissues displayed substantial differences in the levels of inflammatory markers IL-12p40 MIP-1β PDGF-BB and IL-1Ra compared to normal skin samples. Specifically inflammatory infiltration assessed through hematoxylin and eosin staining was markedly elevated in keloid tissues. The expression of IL-12p40 MIP-1β PDGF-BB and IL-1Ra was significantly higher in keloid patients with group A showing noticeable changes following HBOT.

In group A the levels of these inflammatory factors decreased significantly compared to group B. This indicates that HBOT was effective in reducing the inflammatory response within keloid tissues. These observations suggest that HBOT plays a crucial role in mitigating inflammation associated with keloid formation.

In summary the results underscore the potential therapeutic benefits of HBOT in managing keloid-related inflammation by modulating critical inflammatory mediators thus providing a promising approach for keloid treatment.

Conclusion

In conclusion this study demonstrates that hyperbaric oxygen (HBO) therapy significantly reduces the levels of inflammatory mediators in keloid tissues. The key inflammatory factors interleukin-12p40 (IL-12p40) macrophage inflammatory protein-1β (MIP-1β) platelet-derived growth factor-BB (PDGF-BB) and interleukin-1 receptor antagonist (IL-1Ra) were markedly decreased following HBO treatment. These findings suggest that HBO therapy can effectively attenuate the inflammatory response associated with keloid formation. The decrease in inflammatory infiltration observed in keloid tissues post-HBO treatment highlights its potential as a valuable therapeutic option for managing keloid scars.

The significance of these results lies in the potential for HBO therapy to modulate the inflammatory environment in chronic conditions like keloids offering a promising intervention that can be integrated into existing treatment protocols. Future research should aim to optimize HBO therapy parameters such as pressure and duration to maximize its therapeutic benefits. Expanding the scope of research to include a larger patient cohort and diverse keloid presentations will further validate these findings and refine the application of HBO therapy in clinical practice.